nflammatory markers in patients with confirmed atherosclerotic cardiovascular disease
Conditions
Interventions
Group 1: This prospective, multicentre, non-interventional study is being conducted in private cardiology practices. All examinations are carried out as part of routine check-ups without influencing p
Sponsors
BNK Service GmbH
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age = 18 years Signed informed consent form from the patient Confirmed atherosclerotic cardiovascular disease: • coronary heart disease and/or cerebrovascular occlusive disease (cAVK) and/or peripheral arterial occlusive disease (pAVK) confirmed by: - Imaging (CT, carotid duplex ultrasound, MRA) - invasive diagnostics (coronary angiography, PCI) Current hsCRP result available (< 3 months) hsCRP measured outside the context of an acute illness
Exclusion criteria
Exclusion criteria: Existing pregnancy Currently active cancer Current acute infection Immunomodulatory / immunosuppressive treatment (e.g. for COPD, rheumatic conditions, autoimmune diseases)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Prevalence of elevated hsCRP levels (= 2 mg/l) among patients undergoing outpatient secondary cardiological prevention in Germany under real-world conditions - Description of the distribution of hsCRP levels within the study cohort | — |
Secondary
| Measure | Time frame |
|---|---|
| - Description of the clinical and demographic characteristics of patients with elevated hsCRP levels compared with patients with normal hsCRP levels - Analysis of the relationship between hsCRP levels and therapeutic decisions in everyday clinical practice (e.g. adjustment of lipid-lowering therapy, initiation or intensification of pharmacological treatment) - Changes in hsCRP levels over time (12 and 24 months) | — |
Countries
Germany
Outcome results
None listed